Discover Tenders by Drugs Cancer Oncology Sector

Find the most relevant tenders for Drugs Cancer Oncology. Access the latest tender notices from various government and private organizations published across hundreds of websites and newspapers.Obtain complete and accurate information on Drugs Cancer Oncology tenders, including all tender documents, RFPs, RFQs,and more. Utilize our advanced filters to search for Drugs Cancer Oncology tenders by organization, tender value, opening and closing dates, and more.

Filter Your Search

Country

Sector

Region

Funding Agency

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Mebeverine A03Aa04 As Part Of A So Called Open House Model

Deadline: 30 Apr 2026

Germany

Ref. No.: 5728537

EMD:Ref Document

Bid Value: Ref Document

146 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bevacizumab

Deadline: 10 May 2026

Germany

Ref. No.: 5727706

EMD:Ref Document

Bid Value: Ref Document

156 Days Left

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Pomalidomide Atc Code L04Ax06

Deadline: 27 Apr 2026

Germany

Ref. No.: 5727505

EMD:Ref Document

Bid Value: Ref Document

143 Days Left

Conclusion Not Excluding Drug Discount Agreement According To Section 130A Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Aclidinium Bromide Atc Code According To Who R03Bb05

Deadline: 28 Feb 2026

Germany

Ref. No.: 5727483

EMD:Ref Document

Bid Value: Ref Document

85 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Tacrolimus L04Ad02 As Part Of A So Called Open House Model

Deadline: 30 Apr 2026

Germany

Ref. No.: 5726196

EMD:Ref Document

Bid Value: Ref Document

146 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Sirolimus L04Ah01 As Part Of A So Called Open House Model

Deadline: 30 Apr 2026

Germany

Ref. No.: 5721216

EMD:Ref Document

Bid Value: Ref Document

146 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Bevacizumab

Deadline: 10 May 2026

Germany

Ref. No.: 5720077

EMD:Ref Document

Bid Value: Ref Document

156 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Rituximab

Deadline: 11 May 2026

Germany

Ref. No.: 5719969

EMD:Ref Document

Bid Value: Ref Document

157 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab

Deadline: 11 May 2026

Germany

Ref. No.: 5719627

EMD:Ref Document

Bid Value: Ref Document

157 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Estradiol G03Ca03 As Part Of A So Called Open House Model

Deadline: 30 Apr 2026

Germany

Ref. No.: 5719391

EMD:Ref Document

Bid Value: Ref Document

146 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab

Deadline: 11 May 2026

Germany

Ref. No.: 5718497

EMD:Ref Document

Bid Value: Ref Document

157 Days Left

Conclusion Not Excluding Drug Discount Agreement According To Section 130A Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Budesonide Atc Code According To Who A07Ea06

Deadline: 30 Apr 2026

Germany

Ref. No.: 5718312

EMD:Ref Document

Bid Value: Ref Document

146 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Rituximab

Deadline: 11 May 2026

Germany

Ref. No.: 5716614

EMD:Ref Document

Bid Value: Ref Document

157 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Cariprazine N05Ax15 As Part Of A So Called Open House Model

Deadline: 30 Apr 2026

Germany

Ref. No.: 5714435

EMD:Ref Document

Bid Value: Ref Document

146 Days Left

Open House Drug Discount Agreements Abatacept Atc Code L04Aa24

Deadline: 05 May 2026

Germany

Ref. No.: 5701703

EMD:Ref Document

Bid Value: Ref Document

151 Days Left

Showing 32626 to 32640 of 32755 results

‹
1
2
...
2173
2174
2175
2176
2177
2178
2179
...
2183
2184
›

Discover Tenders by Drugs Cancer Oncology Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by Drugs Cancer Oncology Sector

Filter Your Search

FREE Trial plan for all new users!